Journal
JOURNAL OF NEUROCHEMISTRY
Volume 85, Issue 5, Pages 1208-1215Publisher
BLACKWELL PUBLISHING LTD
DOI: 10.1046/j.1471-4159.2003.01745.x
Keywords
Alzheimer's disease; amyloid beta protein; beta-amyloid precursor protein; gelatinase; human cerebrovascular smooth muscle cells; matrix metalloproteinase
Categories
Funding
- NHLBI NIH HHS [HL-49566] Funding Source: Medline
- NIA NIH HHS [AG16223] Funding Source: Medline
- NINDS NIH HHS [NS-35781] Funding Source: Medline
Ask authors/readers for more resources
Cerebral amyloid angiopathy (CAA) is a major pathological feature of Alzheimer's disease and related disorders. Human cerebrovascular smooth muscle (HCSM) cells, which are intimately associated with CAA, have been used as an in vitro model system to investigate pathologic interactions with amyloid beta protein (Abeta). Previously we have shown that pathogenic forms of Abeta induce several pathologic responses in HCSM cells including fibril assembly at the cell surface, increase in the levels of Abeta precursor, and apoptotic cell death. Here we show that pathogenic Abeta stimulates the expression and activation of matrix metalloproteinase-2 (MMP-2). Furthermore, we demonstrate that the increase in MMP-2 activation is largely caused by increased expression of membrane type-1 (MT1)-MMP expression, the primary MMP-2 activator. Finally, treatment with MMP-2 inhibitors resulted in increased HCSM cell viability in the presence of pathogenic Abeta. Our findings suggest that increased expression and activation of MMP-2 may contribute to HCSM cell death in response to pathogenic Abeta. In addition, these activities may also contribute to loss of vessel wall integrity in CAA resulting in hemorrhagic stroke. Therefore, further understanding into the role of MMPs in HCSM cell degeneration may facilitate designing therapeutic strategies to treat CAA found in AD and related disorders.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available